The global chronic obstructive pulmonary disease (COPD) treatment market by Drug Class (Bronchodilators (Theophyllines, Beta 2-Agonists, and Anticholinergics), Steroids, Phosphodiesterase Type 4 Inhibitors, and Others), By Route of Administration (Inhalation and Oral), By Distribution Channel (Online Pharmacies, Hospital Pharmacies, and Retail Pharmacies), and By Region (North America, Asia Pacific, Latin America, Europe, the Middle East, and Africa) had a market valuation of US$ 14,209.0 million in 2020 and is forecast to grow at a CAGR of 4.9 percent during the forecast period (2021–2028).
Get Sample Report with Latest Insights @
https://www.coherentmarketinsights.com/insight/request-sample/2656
Alliances and agreements, mergers and acquisitions, and product releases are projected to drive considerable growth in the global chronic obstructive pulmonary disease (COPD) treatment market during the forecast period.
The global chronic obstructive pulmonary disease (COPD) treatment market is projected to increase due to active participation by market participants in improving medication adherence in COPD patients, raising awareness about the condition, and research and development. ResMed Inc. announced the official launch of their Mobi portable oxygen concentrator for chronic obstructive pulmonary disease (COPD) and other chronic conditions in the United States in January 2019. The Hailie solution was released in the U.S. in 2018 by Adherium, a virtual care platform firm focused on improving drug adherence and patient outcomes. The Hailie solution is meant to help individuals with asthma or chronic obstructive pulmonary disease (COPD) achieve greater adherence by giving them the tools they need to manage their illness.
In addition, in 2018, Adherium and Vitalus Health teamed together to improve the efficacy of Adherium’s Hailie solution with the Vitalus Health provider system. Over the forecast period, these factors are projected to boost the global chronic obstructive pulmonary disease (COPD) treatment market expansion.
Get PDF Brochure with Latest Insights @
https://www.coherentmarketinsights.com/insight/request-pdf/2656
The COPD Foundation created the COPD Pocket Consultant Guide (PCG) app for healthcare practitioners in 2018, with the goal of assisting with COPD treatment and management. Adherium announced the Hailie Global Brand in 2018, which was a redesign of the previous Smartinhaler brand and featured the free Hailie app, a monitoring solution for asthma and COPD. COPD360, an innovative strategy to speed research and create novel treatment options for chronic obstructive pulmonary disease, was introduced in 2015 by the COPD Foundation (COPD). COPD360 will enroll roughly 125,000 patients who have volunteered to contribute their healthcare data in the centralized system, allowing researchers to study patient-reported outcomes and additional observations. AstraZeneca is the initiative’s initial sponsor.
Key Takeaways
Due to the increased incidence of COPD and the increasing demand for improved treatment, the global chronic obstructive pulmonary disease (COPD) treatment market is estimated to grow at a CAGR of 9% over the forecast period (2018–2026).
Manufacturers are concentrating their efforts on enhancing existing treatment choices, conducting research & development for new therapies, and raising awareness, all of which are projected to contribute to market growth over the forecast period.
Market companies’ efforts to enhance treatment adherence, illness awareness, and other factors are projected to fuel market expansion over the forecast period.
Key companies contributing in the global chronic obstructive pulmonary disease (COPD) treatment market are Teva Pharmaceutical Industries Ltd., Boehringer Ingelheim, Mylan N.V., AstraZeneca Plc, CHIESI Farmaceutici SpA, Orion Corporation, Sunovion Pharmaceuticals, Inc., Novartis AG, and GlaxoSmithKline plc.
Reasons to Purchase this Report
• Current and future of global Chronic Obstructive Pulmonary Disease (COPD) Treatment market outlook in the developed and emerging markets
• The segment that is expected to dominate the market as well as the segment which holds highest CAGR in the forecast period.
• Regions/countries that are expected to witness the fastest growth rates during the forecast period
• The latest developments, market shares, and strategies that are employed by the major market players
Table of Content
- Research Objective and assumption
- Research Objectives
- Assumptions
- Abbreviations
- Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snippet, By Drug Class
- Market Snippet, By Route of Administration
- Market Snippet, By Distribution Channel
- Market Snippet, By Region
- Coherent Opportunity Map (COM)
- Report Description
- Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restraints
- Market Opportunities
- Regulatory Scenario
- Key Highlights
- Research and Development Collaboration, Mergers, and Acquisitions
- PEST Analysis
- Pipeline Analysis
- Epidemiology
- Market Dynamics
- Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market, By Drug Class, 2016–2026 (US$ Mn)
- Introduction
- Market Share Analysis, 2017 and 2026 (%)
- Y-o-Y Growth Analysis, 2018–2026
- Segment Trends
- Bronchodilators
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016–2026, (US$ Mn)
- Beta 2-Agonists
- Anticholinergics
- Theophyllines
- Phosphodiesterase Type 4 Inhibitors
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016–2026, (US$ Mn)
- Steroids
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016–2026, (US$ Mn)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016–2026, (US$ Mn)
- Introduction
- Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market, By Route of Administration, 2016–2026 (US$ Mn)
- Introduction
- Market Share Analysis, 2017 and 2026 (%)
- Y-o-Y Growth Analysis, 2018–2026
- Segment Trends
- Oral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016–2026, (US$ Mn)
- Inhalation
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016–2026, (US$ Mn)
- Introduction
- Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market, By Distribution Channel, 2016–2026 (US$ Mn)
- Introduction
- Market Share Analysis, 2017 and 2026 (%)
- Y-o-Y Growth Analysis, 2018–2026
- Segment Trends
- Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016–2026, (US$ Mn)
- Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016–2026, (US$ Mn)
- Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016–2026, (US$ Mn)
- Introduction
- Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market, By Regions, 2016–2026 (US$ Mn)
- Introduction
- Market Share Analysis, By Region, 2017 and 2026 (%)
- Y-o-Y Growth Analysis, For Regions, 2018–2026
- North America
- Market Size and Forecast, By Drug Class, 2016–2026 (US$ Mn)
- Market Size and Forecast, By Route of Administration, 2016–2026 (US$ Mn)
- Market Size and Forecast, By Distribution Channel, 2016–2026 (US$ Mn)
- Market Size and Forecast, By Country, 2016–2026 (US$ Mn)
- U.S.
- Canada
- Europe
- Market Size and Forecast, By Drug Class, 2016–2026 (US$ Mn)
- Market Size and Forecast, By Route of Administration, 2016–2026 (US$ Mn)
- Market Size and Forecast, By Distribution Channel, 2016–2026 (US$ Mn)
- Market Size and Forecast, By Country, 2016–2026 (US$ Mn)
- U.K.
- Germany
- Italy
- France
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- Market Size and Forecast, By Drug Class, 2016–2026 (US$ Mn)
- Market Size and Forecast, By Route of Administration, 2016–2026 (US$ Mn)
- Market Size and Forecast, By Distribution Channel, 2016–2026 (US$ Mn)
- Market Size and Forecast, By Country, 2016–2026 (US$ Mn)
- China
- India
- Japan
- ASEAN
- Australia
- South Korea
- Rest of APAC
- Latin America
- Market Size and Forecast, By Drug Class, 2016–2026 (US$ Mn)
- Market Size and Forecast, By Route of Administration, 2016–2026 (US$ Mn)
- Market Size and Forecast, By Distribution Channel, 2016–2026 (US$ Mn)
- Market Size and Forecast, By Country, 2016–2026 (US$ Mn)
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Africa
- Market Size and Forecast, By Drug Class, 2016–2026 (US$ Mn)
- Market Size and Forecast, By Route of Administration, 2016–2026 (US$ Mn)
- Market Size and Forecast, By Distribution Channel, 2016–2026 (US$ Mn)
- Market Size and Forecast, By Country/Region, 2016–2026 (US$ Mn)
- Central Africa
- South Africa
- North Africa
- Middle East
- Market Size and Forecast, By Drug Class, 2016–2026 (US$ Mn)
- Market Size and Forecast, By Route of Administration, 2016–2026 (US$ Mn)
- Market Size and Forecast, By Distribution Channel, 2016–2026 (US$ Mn)
- Market Size and Forecast, By Country, 2016–2026 (US$ Mn)
- GCC
- Israel
- Rest of Middle East
- Introduction
- Competitive Landscape
- Heat Map Analysis
- Company Profiles
- AstraZeneca Plc
- Company Overview
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Orion Corporation
- Company Overview
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Mylan N.V.
- Company Overview
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Boehringer Ingelheim
- Company Overview
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Teva Pharmaceutical Industries Ltd.
- Company Overview
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- GlaxoSmithKline plc
- Company Overview
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Novartis AG
- Company Overview
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Sunovion Pharmaceuticals, Inc.
- Company Overview
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- CHIESI Farmaceutici SpA
- Company Overview
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- AstraZeneca Plc
- Section
- References
- Research Methodology
- About us and Sales Contact
About Us:
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients to achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having an office at global financial capital in the U.S. and sales consultants in the United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies to not-for-profit organizations, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.
Contact:
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
Email: sales@coherentmarketinsights.com
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837